NEONC TECHNOLOGIES HOLDINGS, INC. Unamortized Debt Issuance Expense
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) had Unamortized Debt Issuance Expense of $1.03 million as of 2026-03-31, per its 10-Q filed 2026-05-15.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:UnamortizedDebtIssuanceExpense · last filed 2026-05-15
- 2026-03-31: Unamortized Debt Issuance Expense $1.03M.
- 2025-12-31: Unamortized Debt Issuance Expense $1.20M; Unamortized Debt Issuance Expense as first filed $1.20M.
- 2025-09-30: Unamortized Debt Issuance Expense $1.37M.
- 2025-06-30: Unamortized Debt Issuance Expense $1.53M.
| Period end | Unamortized Debt Issuance Expense | Unamortized Debt Issuance Expense as first filed |
|---|---|---|
| 2026-03-31 | $1.03M 10-Q · filed 2026-05-15 | |
| 2025-12-31 | $1.20M 10-Q · filed 2026-05-15 | $1.20M 10-K · filed 2026-03-31 |
| 2025-09-30 | $1.37M 10-Q · filed 2025-11-14 | |
| 2025-06-30 | $1.53M 10-Q · filed 2025-08-18 | |
| 2025-03-31 | $1.03M 10-Q · filed 2025-05-09 | |
| 2024-12-31 | $1.87M 10-K · filed 2026-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |